PPA
WST icon

Pilgrim Partners Asia’s West Pharmaceutical WST Stock Holding History

Pilgrim Partners Asia’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-180
Closed -$47.2K – 183
2025
Q3 		$47.2K Buy
+180
New +$43.7K 0.02% 96
2025
Q1 		$49.3K Buy
+220
New +$60.6K 0.05% 68

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pilgrim Partners Asia's WST Position: Q4 2025 in Review

Pilgrim Partners Asia sold out of West Pharmaceutical (WST) in Q4 2025, closing a stake of 180 shares — an estimated $47.2K sold.

Pilgrim Partners Asia first reported a position in WST in Q1 2025 and held it in 2 quarters. The position peaked at $49.3K in Q1 2025. 804 funds tracked by Wall St. Rank hold WST as of Q4 2025.

  • Pilgrim Partners Asia reported no remaining West Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Pilgrim Partners Asia sold 180 West Pharmaceutical shares in Q4 2025, an estimated $47.2K.
  • Pilgrim Partners Asia first reported a position in West Pharmaceutical in Q1 2025 and held it in 2 quarters.
  • Pilgrim Partners Asia's West Pharmaceutical position peaked at $49.3K in Q1 2025.
  • 804 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2025.

Based on Pilgrim Partners Asia's 13F filing for Q4 2025, filed 3 Feb 2026.